**Supplemental Table 10. Summary of VFQ-25 Measured at Baseline and Month 12 Visits, mean (± standard deviation) [Range]**

|  |  |  |
| --- | --- | --- |
| **Visit** | **SGDD**N=22 for BaselineN=14 for month 12 | **CPC**N=19 for BaselineN=13 for month 12 |
| General Health |
| Screening/Baseline  | **62.5\* (±21.5)**[25 – 100] | **48.7\* (±21.2)**[25 – 100] |
| Month 12  | 58.9 (±23.2)[25 – 100] | 53.8 (±20.0)[25 – 100] |
| Change | -1.8 (±20.7)[-50 – 25] | 6.3 (±24.1)[-25 – 50] |
| General Vision |
| Screening/Baseline  | 64.5 (±23.0)[20 – 100] | 63.2 (±15.3)[40 – 80] |
| Month 12  | 64.3 (±21.0)[20 – 80] | 70.8 (±22.5)[20 – 100] |
| Change | 0.0 (±17.5)[-40 – 40] | 6.7 (±19.7)[-40 – 40] |
| Mental Health |
| Screening/Baseline  | 55.4 (±28.8)[0 – 100] | 56.9 (±30.0)[12.5 – 100] |
| Month 12  | 57.6 (±28.1)[12.5 – 93.8] | 68.3 (±30.0)[6.3 – 100] |
| Change | -0.9 (±14.7)[-25 – 18.8] | 5.1 (±27.7)[-25 – 81.3] |
| Distance Activity |
| Screening/Baseline  | 65.8 **(**±24.2)[16.7 – 100] | 63.5(±25.4)[16.7 – 100] |
| Month 12  | 75.8 (±20.2)[41.7 – 100] | 63.9 (±28.1)[16.7 – 100] |
| Change | 14.2 (±20.4)[-8.3 – 58.3] | 8.3 (±19.5)[25 – 41.7] |
| Near Activity |
| Screening/Baseline  | 66.3 (±21.0)[25 – 100] | 62.7 (±20.5)[25 – 100] |
| Month 12  | 71.2 (±22.7)[25 – 100] | 59.0 (±27.3)[8.3 – 100] |
| Change | 9.6 (±11.7)\*[-8.3 – 33.3] | -2.8 (±21.7)[-66.7 – 16.7] |
| Peripheral Vision |
| Screening/Baseline  | 60.2 (±24.0)[25 – 100] | 59.2 (±33.6)[25 – 100] |
| Month 12  | 62.5 (±23.5)[25 – 100] | 63.5 (±33.3)[0 – 100] |
| Change | 3.6 (±13.4)[-25 – 25] | 4.2 (±38.2)[-75 – 75] |
| Color Vision |
| Screening/Baseline  | 86.4 (±22.8)[25 – 100] | 77.6 (±26.2)[25 – 100] |
| Month 12  | 91.1 (±23.2)[25 – 100] | 76.9 (±25.9)[25 – 100] |
| Change | 1.8 (±6.7)[0 – 25] | -6.3 (±32.2)[-75 – 75] |
| Ocular Pain |
| Screening/Baseline  | 76.2 (±28.6)[0 – 100] | 70.4 (±16.3)[37.5 – 100] |
| Month 12  | 83.0 (±20.0)[50 – 100] | 81.7 (±19.5)[37.5 – 100] |
| Change | 8.0 (±21.7)[-25 – 50] | 10.4 (±21.2)[-37.5 – 50] |
| Driving |
| Screening/Baseline  | 63.1 (±25.0)[16.7 – 100] | 55.4 (±13.7)[37.5 – 100] |
| Month 12  | 56.5 (±17.6)[33.3 – 75] | 65.8 (±14.9)[41.7 – 83.3] |
| Change | -2.8 (±14.4)[-16.7 – 25] | 9.2 (±20.2)[-8.3 – 50] |
| Dependency |
| Screening/Baseline  | 50.2 (±22.5)[6 – 72] | 46.7 (±22.8)[6 – 72] |
| Month 12  | 49.3 (±24.4)[6 – 72] | 54.9 (±23.2)[0 – 72] |
| Change | -1.3 (±10.3)[-18 – 18] | 2.0 (±22.4)[-30 – 54] |
| Social Functioning |
| Screening/Baseline  | 83.1 (±18.7)[25 – 100] | 82.7 (±21.5)[37.5 – 100] |
| Month 12  | 83.3 (±26.3)[25 – 100] | 76.0 (±34.8)[12.5 – 100] |
| Change | 2.1 (±10.4)[-12.5 – 25] | -7.3 (±36.7)[-75 – 50] |
| Role Difficulty |
| Screening/Baseline  | 54.8 (±31.2)[0 – 100] | 61.8 (±26.8)[12.5 – 100] |
| Month 12  | 63.4 (±25.7)[0 – 100] | 70.2 (±31.7)[0 – 100] |
| Change | 5.4 (±34.9)[-75 – 62.5] | 2.1 (±33.1)[-87.5 – 50] |

Abbreviations: SGDD=second glaucoma drainage device; CPC=cyclophotocoagulation; BCVA=best-corrected visual acuity.

Due to missing data, the mean of the differences in BCVA between baseline and each follow-up visit do not equal the mean changes in BCVA.

\* for *P* < 0.05, \*\* for *P* < 0.01, and \*\*\* for *P* < 0.001